Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III TrialJ-P. Machiels, Ezra E.W. Cohen, Makoto Tahara et al.|Annals of Oncology|2014Cited by 11
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Tim Henrik Brümmendorf, Robert I. Haddad et al.|RWTH Publications (RWTH Aachen)|2015Cited by 0